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Summary Key Points 
• According to the most recent FluView report, seasonal influenza activity continues 
to increase in the United States. 
• During week 47 (the week ending November 25, 2017), several flu activity 
indicators were higher than is typically seen for this time of year.  
• The proportion of people seeing their health care provider for influenza-like-illness 
(ILI) is above the national baseline for the first time this season. 
• So far, influenza A(H3N2) viruses have been most common this season. 
• Flu is difficult to predict. It’s not possible to say when the 2017-2018 flu season will 
begin, peak or end, how severe it will be, or what viruses will predominate. 
• Each flu season, flu causes millions of illnesses, hundreds of thousands of 
hospitalizations and thousands or sometimes tens of thousands of deaths. 
• The Centers for Disease Control and Prevention (CDC) recommends annual flu 
vaccination for everyone 6 months and older as soon as possible. 
• CDC recommends injectable influenza vaccine this season (flu shots). 
• There is no preferential recommendation for one flu shot over another. 
• It takes about two weeks after vaccination for protection to set in.  
• Now is a good time to get vaccinated. 
• There are many reasons to get a flu vaccine. 
1. While flu vaccine can vary in how well it works, it is the best way to prevent 
flu illness and serious flu complications, including those that can result in 
hospitalization. 
2. Even with vaccine effectiveness in the range of 30 to 60 percent, flu 
vaccination prevents millions of illnesses and tens of thousands of flu-related 
hospitalizations each year. 
3. We cannot know which viruses will circulate over the season and which virus 
will predominate. Flu vaccine protects against three or four different flu 
viruses, depending on which vaccine you get.  
4. A 2017 study was the first of its kind to show that flu vaccination can 
significantly reduce a child’s risk of dying from influenza. 
CDC Influenza Division Key Points          
November 27, 2017 
Page 2 of 5 
 
5. Getting vaccinated yourself protects people around you, including those who 
are more vulnerable to serious flu illness, like babies and young children, 
older people, and people with certain chronic health conditions. 
6. While flu vaccine is not perfect and some people who get vaccinated may still 
get flu, there is some data to suggest that flu vaccination may make illness 
milder. 
• Manufacturers report having shipped more than 148 million doses of flu vaccine as 
of October 20, 2017. 
• The total projected supply of vaccine in the United States this season is between 
151 million and 166 million doses of flu vaccine. About 119 million doses will be 
quadrivalent vaccine. 
• Go to https://vaccinefinder.org  or www.cdc.gov/flu  to find a location near you 
where you can get vaccinated. 
 
Flu Activity 
 
FluView Activity Update (Key Flu Indicators)  
According to this week’s FluView report, seasonal influenza activity increased in the United 
States. The proportion of people seeing their health care provider for influenza-like-illness 
(ILI) is above the national baseline for the first time this season. Influenza A(H3N2) 
viruses were most commonly reported during week 47 (the week ending November 25, 
2017) and have been the predominant virus so far this season. Several flu activity 
indicators were higher than is typically seen for this time of year. Four states reported 
widespread flu activity, ten states reported regional flu activity and 24 states reported 
local influenza activity. Flu vaccine is the best available way to protect against influenza. 
CDC recommends that everyone 6 months and older get an injectable flu vaccine as soon 
as possible. Below is a summary of the key flu indicators for the week ending November 
25, 2017: 
• Influenza-like Illness Surveillance: For the week ending November 25, the 
proportion of people seeing their health care provider for influenza-like illness (ILI) 
was 2.3% which is above the national baseline of 2.2%. This increase in the 
percentage of patient visits for ILI during week 47 might be influenced in part by a 
reduction in routine health care visits during the holidays, as has occurred in 
previous seasons.  Regions 1, 4, 6 and 7 reported a proportion of outpatient visits 
for ILI at or above their region-specific baseline levels. 
o Additional ILINet data, including national, regional, and select state-level 
data for the current and previous seasons, can be found at 
http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
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• Influenza-like Illness State Activity Indicator Map: Three states experienced 
high ILI activity (Louisiana, Mississippi, and South Carolina). One state experienced 
moderate ILI activity (Georgia). Ten states (Alabama, Alaska, Arizona, Hawaii, 
Massachusetts, Nebraska, Oklahoma, South Dakota, Texas, and Virginia) 
experienced low ILI activity. The District of Columbia, New York City, and 36 states 
experienced minimal ILI activity (Arkansas, California, Colorado, Connecticut, 
Delaware, Florida, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, 
Maryland, Michigan, Minnesota, Missouri, Montana, Nevada, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oregon, 
Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Washington, West Virginia, 
Wisconsin and Wyoming). Data was insufficient to calculate an ILI activity level 
from Puerto Rico.  
o Additional data, including data for previous seasons, can be found at 
https://gis.cdc.gov/grasp/fluview/main.html  
• Geographic Spread of Influenza Viruses: Widespread influenza activity was 
reported by four states (Georgia, Louisiana, Massachusetts, and Oklahoma). 
Regional influenza activity was reported by Guam and ten states (Arkansas, 
Connecticut, Kentucky, Maine, Mississippi, New Hampshire, North Dakota, Oregon, 
South Carolina, and Washington). Local influenza activity was reported by Puerto 
Rico and 24 states (Alabama, Alaska, Arizona, California, Colorado, Florida, Hawaii, 
Illinois, Kansas, Maryland, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, 
New York, Ohio, Pennsylvania, South Dakota,  Tennessee, Texas, Utah, Wisconsin, 
and Wyoming). Sporadic activity was reported by the District of Columbia, the U.S. 
Virgin Islands and 12 states (Delaware, Idaho, Indiana, Iowa, Michigan, Montana, 
Nevada, North Carolina, Rhode Island, Vermont, Virginia, and West Virginia). No 
activity was reported by one state (West Virginia. Guam, Puerto Rico, and one state 
(Nebraska). Geographic spread data show how many areas within a state or 
territory are seeing flu activity. 
o Additional data are available at: 
https://gis.cdc.gov/grasp/fluview/FluView8.html.   
• Flu-Associated Hospitalizations: Since October 1, 2017, 566 laboratory-
confirmed influenza-associated hospitalizations have been reported through the 
Influenza Hospitalization Network (FluSurv-NET), a population-based surveillance 
network for laboratory-confirmed influenza-associated hospitalizations. This 
translates to a cumulative overall rate of 2.0 hospitalizations per 100,000 people in 
the United States. 
o The highest hospitalization rates are among people 65 years and older (7.3 
per 100,000), followed by adults aged 50-64 years (2.4 per 100,000), and 
children younger than 5 years (1.6 per 100,000). During most seasons, 
children younger than 5 years and adults 65 years and older have the 
highest hospitalization rates. 
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o Additional data, including hospitalization rates during other influenza 
seasons, can be found at 
http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and 
http://gis.cdc.gov/grasp/fluview/FluHospChars.html.  
 
• Mortality Surveillance:  
o The proportion of deaths attributed to pneumonia and influenza (P&I) was 5.7% 
for the week ending November 11, 2017 (week 45). This percentage is below 
the epidemic threshold of 6.5% for week 45 in the National Center for Health 
Statistics (NCHS) Mortality Surveillance System.  
o Region and state-specific data are available at 
https://gis.cdc.gov/grasp/fluview/mortality.html.     
• Pediatric Deaths:  
o No influenza-associated pediatric deaths were reported to CDC during week 
47. 
o Five influenza-associated pediatric deaths for the 2017-2018 season have been 
reported to CDC. 
o Additional information on pediatric deaths is available on FluView Interactive at: 
https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.  
• Laboratory Data:  
o Nationally, the percentage of respiratory specimens testing positive for influenza 
viruses in clinical laboratories during the week ending November 25 was 7.2%. 
o Regionally, the three week average percent of specimens testing positive for 
influenza in clinical laboratories ranged from 1.9% to 8.6%. 
o During the week ending November 25, of the 1,051 (7.2%) influenza-positive 
tests reported to CDC by clinical laboratories, 795 (75.6%) were influenza A 
viruses and 256 (24.4%) were influenza B viruses. 
o The most frequently identified influenza virus type reported by public health 
laboratories was influenza A virus.   
o During the week ending November 25, 186 (88.6%) of the 210 influenza-
positive tests reported to CDC by public health laboratories were influenza A 
viruses and 24 (11.4%) were influenza B viruses. Of the 186 influenza A viruses 
that were subtyped, 168 (90.3%) were H3N2 viruses and 18 (9.7%) were 
(H1N1)pdm09 viruses. 
o The majority of the influenza viruses collected from the United States during 
October 1 through November 25, 2017 were characterized antigenically and 
genetically as being similar to the cell-grown reference viruses representing the 
2017–18 Northern Hemisphere influenza vaccine viruses. 
o Of the influenza viruses tested and collected during October 1-November 25, 
2017, none were found to be resistant to antiviral medications (i.e. oseltamivir, 
zanamivir, or peramivir).  
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FluView (http://www.cdc.gov/flu/weekly/fluactivitysurv.htm) is available – and past issues 
are archived (http://www.cdc.gov/flu/weekly/pastreports.htm) – on the CDC website. 
Note: Delays in reporting may mean that data changes over time. The most up to date 
data for all weeks during the 2017-2018 season can be found on the current 
FluView(http://www.cdc.gov/flu/weekly/) and FluView Interactive 
(https://www.cdc.gov/flu/weekly/fluviewinteractive.htm). 
 
 
 
 
 
 
 
 
 
